2014 HESI Annual Meeting

The HESI Annual Meeting featured presentations and events that celebrated HESI’s past, present, and future, including engaging lectures from some of our most influential thought leaders over the years. Participants learned about innovative collaborations across the NGO, academic, government, and industrial sectors to improve human health and the environment; discussed proposals that would benefit from HESI’s multi-sector collaborative approach; and explored the promise and challenges of continuing HESI’s rich history of innovative parterships and achieving scientific impact.

The Program Book for the 2014 HESI Annual Meeting:

Tab 1 – Meeting Agenda
Tab 2 – HESI Business Meeting
Tab 3 – Emerging Issues Session
Tab 4 – HESI Today
Tab 5 – HESI History
Tab 6 – Speaker Bios
Tab 7 – Participants

HESI CITE ‘Mini-symposium’: Creating Scientific Impact & Innovation Through Effective Collaborations

The CSSI Apporoach to Innovative Teams

• Dr. Jerry Lee (National Cancer Institute, Center for Strategic Scientific Initiatives)

Resource Use – Spurring Efficient Innovation through CrowdSourcing – The Harvard Catalyst Model

• Dr. Eva Guinan (Harvard Medical School)

Evaluating Impact of NIH Clinical and Translational Science Awards Program

• Dr. Deborah DiazGranados (Virginia Commonwealth University)

HESI’s Role in Translational Science via CITE

• Dr. Brian Berridge (GlaxoSmithKline, HESI Trustee)

HESI Opening Science Plenary: 25 Years of Positive Impact on Science and Health

25 Years of Impact and Achievement

• Dr. Kendall Wallace (University of Minnesota Medical School, HESI Chair)

A Perspective on HESI’s Scientific Committees

• Dr. Michael P Holsapple (Covance, former HESI Executive Director)

Developmental and Reproductive Toxicology Technical Committee

• Dr. Wafa Harrouk (US Food and Drug Administration)

Bioaccumulation Technical Committee

• Dr. John Nichols (US Environmental Protection Agency)

Genetic Toxicology Technical Committee

• Dr. Stefan Pfuhler (Procter & Gamble Company)

RISK21 Technical Committee

• Prof. Alan Boobis (Imperial College London)

HESI Looking Forward – The Next 25 Years

• Syril D. Pettit (HESI Executive Director)

Science Session: Bridging Technical Disciplines & Scientific Partners for Improved Human & Environmental Health: Perspectives from Nonprofit Thought Leaders

Advancing a Quality of Life Agenda: Innovation, Ingenuity & Advocacy

• Dr. Rebecca Kirch (American Cancer Society)

Generating Tailored Solutions from Big Data: The Future of Health and Environmental Data Interrogation. In Silico Modeling of Systems Biological Networks

• Dr. Nathan Price (Institute for Systems Biology)

Innovative Apporaches to Partnership to Support Public Health

• Dr. Jason Clay (World Wildlife Fund)

HESI Emerging Issues Session

HESI’s Approach to identifiying Emerging Science Priorities

• Dr. Hal Zenick (US Environmental Protection Agency, EIC Chair)
• Dr. Ruth Roberts (AstraZeneca R&D; EIC Vice Chair)

Proposals for Consideration by HESI Constituency

Framework for intelligent non-animal alternative methods for safety assessment

• Dr. J. Craig Rowlands (Dow Chemical Company)
• Prof. Alan Boobis (Imperial College London)

Strategies to integrate exposure, PBPK models and data on metabolism to predict plasma levels of compounds and their metabolites that are directly comparable to in vitro toxicology results

• Dr. Timothy Pastoor (Syngenta)

A new exposure science emerging from new demands, technology, and big data

• Dr. Rosemary Zaleski (ExxonMobil Biomedical Sciences)
• Dr. Hal Zenick (US Environmental Protection Agency)

Environmental chemicals and low-dose non-monotonic dose-responses: Is there an impact on risk assessment-based study design and interpretation?

• Dr. Sue Yi (Syngenta)
• Dr. Rita Schoeny (US Environmental Protection Agency)